Classification and Staging of Hepatocellular Carcinoma: An Aid to Clinical Decision-Making

Clinics in Liver Disease

Volumn 19, Issue 2, 2015, Pages 277-294

  Addissie, Benyam D ^a   Roberts, Lewis R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Classification; Hepatocellular carcinoma; Treatment selection; Tumor staging

Indexed keywords

ANTINEOPLASTIC AGENT;

ABLATION THERAPY; ARTIFICIAL EMBOLISM; BARCELONA CLINIC LIVER CANCER STAGING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER OF THE LIVER ITALIAN PROGRAM; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL DECISION MAKING; HONG KONG LIVER CANCER PROGNOSTIC STAGING SCHEME; HUMAN; JAPAN INTEGRATED STAGING; LIVER CELL CARCINOMA; LIVER SURGERY; LIVER TRANSPLANTATION; LOCAL THERAPY; OKUDA CLASSIFICATION; PROTON THERAPY; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMIC THERAPY; TRANSARTERIAL CHEMOEMBOLIZATION; TRANSARTERIAL CHEMOINFUSION; TRANSARTERIAL RADIOEMBOLIZATION; CARCINOMA, HEPATOCELLULAR; CLASSIFICATION; DECISION MAKING; DECISION SUPPORT SYSTEM; LIVER NEOPLASMS; LIVER RESECTION; PATHOLOGY; PROCEDURES; RADIOSURGERY;

ABLATION TECHNIQUES; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DECISION MAKING; DECISION SUPPORT TECHNIQUES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM STAGING; PROTON THERAPY; RADIOSURGERY;

EID: 84928822051     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2015.01.011     Document Type: Review

References (49)

1. Denoix P. The treatment of tumors as a function of our knowledge concerning the role of the host. Rev Fr Etud Clin Biol 1965, 10(6):583-586. [in French].
2. Greene F.L., Sobin L.H. The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin 2008, 58(3):180-190.
3. Lu W., Dong J., Huang Z., et al. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. JGastroenterol Hepatol 2008, 23(12):1874-1878.
4. Okuda K., Ohtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56(4):918-928.
5. Anew prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998, 28(3):751-755.
6. Ueno S., Tanabe G., Sako K., et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 2001, 34(3):529-534.
7. Levy I., Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002, 50(6):881-885.
8. Zhao W.H., Ma Z.M., Zhou X.R., et al. Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World J Gastroenterol 2002, 8(2):237-242.
9. Kudo M., Chung H., Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging score (JIS score). JGastroenterol 2003, 38(3):207-215.
10. Kitai S., Kudo M., Minami Y., et al. Anew prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan Integrated Staging score. Intervirology 2008, 51(Suppl 1):86-94.
11. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19(3):329-338.
12. Marrero J.A., Fontana R.J., Barrat A., et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005, 41(4):707-716.
13. Cillo U., Vitale A., Grigoletto F., et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. JHepatol 2006, 44(4):723-731.
14. Wang J.H., Changchien C.S., Hu T.H., et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma: survival analysis of 3892 patients. Eur J Cancer 2008, 44(7):1000-1006.
15. Yau T., Tang V.Y., Yao T.J., et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014, 146(7):1691-1700.e3.
16. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. NEngl J Med 1996, 334(11):693-699.
17. Yoo H.Y., Patt C.H., Geschwind J.F., et al. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. JClin Oncol 2003, 21(23):4329-4335.
18. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33(6):1394-1403.
19. Schlansky B., Chen Y., Scott D.L., et al. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry. Liver Transpl 2014, 20(9):1045-1056.
20. Graziadei I.W., Sandmueller H., Waldenberger P., et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003, 9(6):557-563.
21. Mazzaferro V., Battiston C., Perrone S., et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004, 240(5):900-909.
22. Bruix J., Castells A., Bosch J., et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996, 111(4):1018-1022.
23. Roayaie S., Haim M.B., Emre S., et al. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience. Ann Surg Oncol 2000, 7(10):764-770.
24. Teh S.H., Christein J., Donohue J., et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. JGastrointest Surg 2005, 9(9):1207-1215. [discussion: 1215].
25. Lisotti A., Azzaroli F., Buonfiglioli F., et al. Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. Hepatology 2014, 59(2):643-650.
26. Makuuchi M., Kosuge T., Takayama T., et al. Surgery for small liver cancers. Semin Surg Oncol 1993, 9(4):298-304.
27. Kudo M., Matsui O., Izumi N., et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer 2014, 3(3-4):458-468.
28. Ishizawa T., Hasegawa K., Aoki T., et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008, 134(7):1908-1916.
29. Ho M.C., Huang G.T., Tsang Y.M., et al. Liver resection improves the survival of patients with multiple hepatocellular carcinomas. Ann Surg Oncol 2009, 16(4):848-855.
30. Brunello F., Veltri A., Carucci P., et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008, 43(6):727-735.
31. Shiina S., Tateishi R., Imamura M., et al. Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors. Liver Int 2012, 32(9):1434-1442.
32. Thompson S.M., Callstrom M.R., Butters K.A., et al. Role for putative hepatocellular carcinoma stem cell subpopulations in biological response to incomplete thermal ablation: invitro and invivo pilot study. Cardiovasc Intervent Radiol 2014, 37(5):1343-1351.
33. Seong J., Park H.C., Han K.H., et al. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003, 55(2):329-336.
34. Mornex F., Girard N., Beziat C., et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies: mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006, 66(4):1152-1158.
35. Komatsu S., Fukumoto T., Demizu Y., et al. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer 2011, 117(21):4890-4904.
36. Kang J.W., Kim J.H., Ko G.Y., et al. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt. Acta Radiol 2012, 53(5):545-550.
37. Kuo Y.C., Kohi M.P., Naeger D.M., et al. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol 2013, 36(5):1336-1343.
38. Moreno-Luna L.E., Yang J.D., Sanchez W., et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol 2013, 36(3):714-723.
39. Donahue L.A., Kulik L., Baker T., et al. Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. JVasc Interv Radiol 2013, 24(1):74-80.
40. Padia S.A., Chewning R.H., Kogut M.J., et al. Outcomes of locoregional tumor therapy for patients with hepatocellular carcinoma and transjugular intrahepatic portosystemic shunts. Cardiovasc Intervent Radiol 2014, [Epub ahead of print].
41. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. NEngl J Med 2008, 359(4):378-390.
42. Kostner A.H., Sorensen M., Olesen R.K., et al. Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability. ScientificWorldJournal 2013, 2013:931972.
43. Arao T., Ueshima K., Matsumoto K., et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 2013, 57(4):1407-1415.
44. Horwitz E., Stein I., Andreozzi M., et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov 2014, 4(6):730-743.
45. Oie S., Ono M., Fukushima H., et al. Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells. Mol Cancer Ther 2007, 6(8):2310-2318.
46. Qin S., Bai Y., Lim H.Y., et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. JClin Oncol 2013, 31(28):3501-3508.
47. Choi J.Y. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea. Oncology 2011, 81(Suppl 1):141-147.
48. Borzio M., Fornari F., De Sio I., et al. Adherence to American association for the study of liver diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. Future Oncol 2013, 9(2):283-294.
49. Torzilli G., Belghiti J., Kokudo N., et al. Asnapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West study group. Ann Surg 2013, 257(5):929-937.